Insilico Medicine Announces Industry’s First Longevity Board to Accelerate AI-Driven Aging Research for Drug Discovery (IMAGE)
Caption
The initiative provides scientific oversight and strategic guidance for AI-enabled aging research and drug discovery, accelerating the development of therapeutics that target the fundamental biological processes of aging and advancing a shift from reactive disease care to proactive healthspan and peakspan extension. The Board will oversee the work in life models, biomarkers of aging, identification of dual-purpose targets implicated in aging, longevity and disease, and clinical development validating the effects of therapeutics on the hallmarks of aging using biomarkers and foundation models.
Credit
Insilico Medicine
Usage Restrictions
None
License
Original content